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Dominant mutations in p97/VCP (valosin-containing protein) cause
a rare multisystem degenerative disease with varied phenotypes
that include inclusion body myopathy, Paget’s disease of bone,
frontotemporal dementia, and amyotrophic lateral sclerosis. p97
disease mutants have altered N-domain conformations, elevated
ATPase activity, and altered cofactor association. We have now
discovered a previously unidentified disease-relevant functional
property of p97 by identifying how the cofactors p37 and p47
regulate p97 ATPase activity. We define p37 as, to our knowledge,
the first known p97-activating cofactor, which enhances the cata-
lytic efficiency (kcat/Km) of p97 by 11-fold. Whereas both p37 and
p47 decrease the Km of ATP in p97, p37 increases the kcat of p97. In
contrast, regulation by p47 is biphasic, with decreased kcat at
low levels but increased kcat at higher levels. By deleting a re-
gion of p47 that lacks homology to p37 (amino acids 69–92), we
changed p47 from an inhibitory cofactor to an activating cofac-
tor, similar to p37. Our data suggest that cofactors regulate p97
ATPase activity by binding to the N domain. Induced conforma-
tion changes affect ADP/ATP binding at the D1 domain, which
in turn controls ATPase cycling. Most importantly, we found
that the D2 domain of disease mutants failed to be activated
by p37 or p47. Our results show that cofactors play a critical role
in controlling p97 ATPase activity, and suggest that lack of cofactor-
regulated communication may contribute to p97-associated dis-
ease pathogenesis.
AAA ATPase | p97/VCP | MSP1 | p47 | steady-state kinetics
The p97 AAA [ATPase associated with diverse cellular activ-ities; also called VCP (valosin-containing protein)] partic-
ipates in key steps in ubiquitin-dependent protein quality control
(1), autophagy (2, 3), membrane remodeling (4, 5), and numer-
ous other fundamentally important cellular functions. p97 directs
proteins to two major degradation systems: the proteasome and
autophagy pathways. This key role of p97 underscores its impor-
tance in protein homeostasis and strongly implicates p97 in neu-
rodegenerative diseases (6). Dominantly inherited missense
mutations in p97 were initially associated with a rare degenerative
disorder termed inclusion body myopathy with Paget’s disease
of bone and frontotemporal dementia (IBMPFD) (7, 8). Sub-
sequently, it has been found that mutations in p97 cause a wider
spectrum of degenerative diseases that includes amyotrophic lat-
eral sclerosis (9–12) and parkinsonism (13). Thus, the acronym
IBMPFD is insufficient. Moreover, mutations in the heteroge-
neous nuclear ribonucleoproteins hnRNPA2B1 and hnRNPA1
also cause a syndrome similar to conditions associated with VCP
mutations (14). To account for the varied phenotypes and genetic
etiologies of IBMPFD, it has been suggested that the term mul-
tisystem proteinopathy type 1 (MSP1) (14) be used to describe the
phenotypic syndrome associated with mutations in p97. Disease
mutants of p97 contribute to pathology by disrupting autophagosome
(2, 3) and endosome maturation, which leads to vacuolation, weak-
ness, and muscle atrophy (15, 16). However, the molecular
disease mechanisms associated with mutant p97 are still being
investigated, with the eventual hope of developing therapeutic
agents for these serious illnesses.
p97 assembles into a homohexamer, as revealed by X-ray
crystallography (17, 18). A single monomer is composed of an
N domain, which interacts with p97 cofactor proteins, and two
ATPase domains, D1 and D2. The D1 and D2 domains form
stacked hexameric rings, whereas the N domains extend out-
ward, coplanar with the D1 ring. Most of the disease mutations
occur in the N domain, whereas some occur in the D1 or the
N–D1 linker region (see SI Appendix, Fig. S1A for examples). All
p97 disease mutants tested thus far can form stable hexamers
(19, 20) and exhibit increased D2 ATPase activity (19–23).
Disease mutations lead to increased proteolytic susceptibility of
the D2 ring (19). Structural and biochemical studies suggest that
disease mutations alter N-domain and D1 conformations (20, 23,
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24) and cause defects in interdomain communication between
neighboring subunits.
A major role of the N domain is to recruit cofactors (25, 26),
such as the Npl4 (nuclear protein localization homolog 4) and
Ufd1 (ubiquitin fusion degradation 1) heterodimers (27), and an
array of 13 UBX (ubiquitin regulatory X) domain cofactors (28).
By recruiting certain cofactor proteins, the N domain may link
the mechanochemical activity of ATP hydrolysis to the unfolding
or disassembly of substrate proteins. p47, the first p97 UBX
cofactor discovered, is required for p97-mediated membrane
fusion (29). Binding of p47 (also called NSFL1 cofactor p47 or
UBX domain-containing protein 2C) to the N domain of p97
significantly reduces the diameter of the p97 ring (29) and
inhibits wild-type p97 ATPase activity (30). Although actively
studied, the physiological functions of p97–cofactor complexes
and their mechanisms are largely unknown.
X-ray crystallography of p97 has revealed that the N domain of
p97 is conformationally flexible (17, 18), adopting two primary
conformations. In the up conformation, the N domain extends
above the D1 ring, whereas in the down conformation, the
N domain lies coplanar with the D1 ring. The conformation is
nucleotide-dependent, that is, determined by the binding state
of the D1 domain (17). It has been proposed that the flexibility
of the N domain is crucial to ATP hydrolysis, because modi-
fying the N domain reduces ATPase activity. Specifically, re-
ducing N-domain mobility inhibits wild-type p97 ATPase
activity (20). Moreover, removing the N domain (1∼209) alto-
gether was shown to block the enhanced ATPase activity of
a disease mutant (20).
In wild-type p97, the N domains exist in a tightly regulated,
heterogeneous arrangement of up and down conformations. In
contrast, disease mutants exhibit dysregulated N-domain con-
formations (12, 17, 24). Crystal structures of two disease mutants
showed all six N domains of the complex in the up conformation,
a behavior that has been observed in only disease mutants (23).
A recent study found that this uniform arrangement is a sec-
ondary effect of reduced ADP binding by the D1 domain, whose
state controls N-domain conformation (23).
Altered conformation of the N domain in p97 disease mutants
is further supported by atypical p97 cofactor binding in cells (31–
33). Decreased binding to a UBX cofactor, UBXD1, is observed
in 293T cells expressing p97 disease mutants and leads to
a blockade of caveolin 1 trafficking (33). Intriguingly, disease
mutants can coimmunoprecipitate more p47 and Npl4/Ufd1
heterodimers than WT p97, suggesting elevated binding affinities
for p47 and Npl4/Ufd1 in mutant cells (31, 33). However, the
consequences of altered binding to cofactors in cells that express
mutant p97 have not been investigated biochemically. To provide
a mechanistic understanding of cofactor-regulated ATPase ac-
tivity, we analyzed the effect of p37 and p47 on the ATPase
activity of WT and disease mutants of p97 in this study.
Results
p37- and p47-Regulated ATPase Activity of WT and Mutant p97.
Pathogenic p97 mutations occur mostly in three regions of p97:
the N domain, the N–D1 linker region, and the D1 domain (SI
Appendix, Fig. S1A; arrows indicate representative mutants from
these regions). These mutants are thought to affect the confor-
mation and ATPase activity of p97. The models of WT and
disease mutants in SI Appendix, Fig. S1B illustrate that (i) both
D1 and D2 domains hydrolyze ATP, and (ii) N domains in
a disease mutant have more up conformations, resulting in ele-
vated basal D2 ATPase activity (20, 23). We first measured the
ATPase activity of purified recombinant proteins and confirmed
that all three mutants (R155H, L198W, and A232E) have higher
basal ATPase activities than WT p97 (Fig. 1A).
To determine whether dysregulated N-domain conformations
might affect p97 cofactor-regulated ATPase activity of disease
mutants, we tested whether p47 affects ATPase activity of
pathogenic p97 mutants and WT p97 in a similar manner. We
measured the p97 ATPase activity of WT, R155H, L198W, and
A232E (at 4.17 nM hexamer) with increasing amounts of p47 (at
0–800 nM monomer) in the presence of 200 μM ATP (Fig. 1B).
For each p97 protein, the % ATPase activity was normalized to the
activity of p97 alone (without p47). We observed a biphasic in-
hibition of WT p97 by p47 (Fig. 1B, phases 1 and 2). At relatively
lower concentrations of p47, p97 ATPase activity was strongly
inhibited (Fig. 1B, phase 1; maximal 68% inhibition at 6.25 nM p47,
indicated by a red arrow), consistent with a previous report (30).
However, when p47 was added at higher stoichiometries than in the
previous report (30), the inhibition was reduced to 30% (Fig. 1B,
phase 2). Similar results were obtained when we carried out p47
titrations with 800 μM ATP for p47-regulated ATPase activity of
WT p97 (SI Appendix, Fig. S1C) and with five times more WT p97
(20.8 nM hexamer, which was associated with a slight upshift of the
curve; Fig. 1D).
For the R155H, L198W, and A232E disease mutants, which
represent three regions of p97 (the N domain, N–D1 linker, and
D1 domain, respectively), we detected a single inhibition phase.
Moreover, their ATPase activity remained 68% inhibited with up
to 800 nM p47 [with 200 μM (Fig. 1B, phase 1) or 800 μM ATP
(SI Appendix, Fig. S1E)]. These results revealed two major dif-
ferences between WT and p97 disease mutants: (i) p47 inhibited
WT p97 threefold faster than the mutants at the initial phase,
and (ii) the disease mutants lacked phase 2 (the rebound phase)
when exposed to p47.
To determine whether this observation applied to other p97
cofactors, we performed similar experiments with the p97 cofactor
known as p37 (also called UBX domain-containing protein 2B).
The protein sequences of p37 and p47 are highly similar, but p37 is
involved in distinct pathways required for Golgi and endoplasmic
reticulum (ER) biogenesis (34–36). Interestingly, p37 activated
WT p97 ATPase activity by 3.7-fold at 100 nM p37. In contrast,
p37 activated p97 disease mutants by only 1.3-fold (see arrows in
Fig. 1C). This pattern was not significantly affected when the ATP
concentration was increased from 200 to 800 μM, for both WT
p97 (SI Appendix, Fig. S1F) and its mutants (SI Appendix, Fig.
S1G). These results define p37 as an activating cofactor of p97
ATPase—distinguishing it from p47, which is predominantly an
Fig. 1. Regulation of p97 ATPase activity by p37 and p47. (A) ATPase ac-
tivity for p97 disease mutants normalized to WT activity and measured with
200 μM ATP (n = 6). For B–D, the activity of each p97 protein was normalized
to its basal activity in the absence of cofactors. A red arrow marks the point
at which the lowest activity was reached. (B and C) Normalized ATPase ac-
tivities of WT, R155H, L198W, and A232E p97 in the presence of increasing
amounts (0–800 nM) of p47 (B) or p37 (C), measured with 200 μM ATP. For B,
n = 12, excluding L198W (n = 6). For C, n = 12. (D) The impact of p47 on
ATPase activity was also measured for D1-E305Q and D2-E578Q p97 mutants
(n = 12). Blue lettering indicates the active ATPase domain in each protein, and
green lettering indicates the Walker B mutant. All error bars indicate ± SD.
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inhibitor. Moreover, there are substantial differences in the p37
control of WT versus mutant p97 ATPase activity.
To examine whether higher concentrations of p47 cause dis-
ease mutants to become less stable (as hexamers) than WT p97
and thereby lack the phase 2 rebound effect, we mixed 1.67 μM
p97 hexamers with 80 μM p47 and fractionated the proteins by
gel filtration. The ratio of p47 to p97 in the gel-filtration ex-
periment corresponds to 200 nM p47 in the titration experiments
(Fig. 1B). Previously, WT p97 has been shown to form a stable
complex with p47 using a gel-filtration column (29). As shown in
SI Appendix, Fig. S2A, both WT and R155H were eluted pre-
dominantly at fractions 18–20, corresponding to p97 hexamers.
A similar amount of p47 was cofractionated with both p97 pro-
teins. The excess amount of p47 formed stable trimers eluted at
fractions 27 and 28 (SI Appendix, Fig. S2B), as seen in previous
reports (29, 37). We concluded that lack of the phase 2 effect
with p97 disease mutants is not due to denaturation of p97 by
excess amounts of p47.
To estimate the amount of p37 or p47 trimer in the titration
experiment, we quantitatively determined the equilibrium bind-
ing constant (KD) for trimer formation for both p37 and p47
using microscale thermophoresis. The KD values were 18.2 nM
(±3.4 nM) and 6.9 nM (±1.9 nM) for p37 and p47, respectively
(SI Appendix, Fig. S2 C and D). This indicates that at 6.9 nM p47,
3.45 nM p47 is in the form of trimers. Interestingly, the transition
point from phase 1 to phase 2 occurred at 6.25 nM p47 (Fig. 1B,
indicated by a red arrow), which is close to the KD of p47 trimer
formation. This result also suggests that the phase 2 rebound
reaches maximal activity when the majority of p47 is in the form
of trimers.
Contribution of D1 and D2 to p37- and p47-Regulated p97 ATPase
Activity. To determine how the D1 and D2 ATPase domains of
WT p97 contribute to p37 and p47 regulation of p97 ATPase
activities, we compared the ATPase activities of WT p97 and
Walker B mutants (D1-E305Q and D2-E578Q, which allow ATP
and ADP binding but block activation of hydrolysis) (22, 38). We
showed that p47 mediates an initial inhibitory phase (phase 1; SI
Appendix, Fig. S1D) that requires catalytically active D1 and D2
ATP hydrolase domains, because both D1-E305Q and D2-
E578Q lacked pronounced inhibition in phase 1 (which was
observed for WT p97) (Fig. 1D). Activation of D1-E305Q was
observed at 25 nM p47 and saturated at 200 nM p47. Thus, the
rebound phase of WT p97 (Fig. 1B, phase 2) is mainly due to
activation of D2 ATPase activity. Slight inhibition (26%) of D2-
E578Q at 6.25 nM p47 (indicated by a red arrow in Fig. 1D)
suggests that the initial inhibition (phase 1, maximal inhibition
68%) was caused by inhibiting both D1 and D2 in WT p97, when
both D1 and D2 are capable of hydrolyzing ATP.
Because D2 is necessary and sufficient for the rebound phase
of WT p97, and because disease mutants do not exhibit a re-
bound phase, we next evaluated how p47 regulates the D2 ac-
tivity of the R155H or A232E disease mutants. The p47 titration
curve for the R155H, D1-E305Q double mutant is relatively flat,
with slight inhibition. It also lacks the activation phase observed
for D1-E305Q (SI Appendix, Fig. S1H). The same result was
obtained for A232E, D1-E305Q (SI Appendix, Fig. S1I). The
titration curve for the p37 cofactor of WT p97 overlaps with the
curve for D1-E305Q p97, whereas the curve for D2-E578Q p97
is flat (SI Appendix, Fig. S1J). Taken together, our data indicate
that p37 activates D2 ATPase activity of WT p97, whereas p47
has dual effects on D1 and D2 activity in a concentration-
dependent manner. Specifically, p47 inhibits both D1 and D2 at
lower concentrations, whereas p47 slightly inhibits D1 but acti-
vates D2 at higher concentrations. Most importantly, the p37-
mediated activation and the p47-mediated phase 2 rebound are
not seen with the R155H, L198W, and A232E disease mutants.
These results highlight the defect in cofactor-mediated ATPase
activation in p97 disease mutants, and clearly show a defective
function of p97 disease mutants.
Identification of the Region of p47 That Is Responsible for Phase 1
Inhibition of WT p97.We found that p37 activates p97, without the
phase 1 inhibitory effect observed for p47. To determine the
origin of this major difference, we first searched for published
structures of p47. Although p47 was discovered in 1997 (29), no
X-ray or NMR structures for full-length p47 have been published.
Electron microscopy has demonstrated that distinct conforma-
tional changes occur in p97 following binding to full-length p47 or
partial versions of p47 (26, 29, 39). Specifically, binding to p47
reduces the diameter of the central channel within the p97 hex-
americ ring and changes the shape of the p97 ring from a hexagon
to a pinwheel (29). Detailed NMR or X-ray structures are avail-
able for different truncated p47 domains, such as the N-terminal
UBA (ubiquitin-associated) domain (37), the middle SEP (Shp
eyes-closed p47) domain (37, 40), and the C-terminal UBX do-
main (25, 41). The obvious difference between p37 and p47 is that
p37 lacks the UBA domain. Also, the p97–p37 pathway does not
require ubiquitin for its function in maintaining Golgi structure
during interphase and in reassembling the organelle during the
later stages of mitosis (34). We therefore deleted the UBA do-
main (amino acids 1–46) from p47 to construct ΔUBA p47 and
measured WT p97 ATP activity in the presence of increasing
amounts of ΔUBA p47. The titration curves of WT p47 and
ΔUBA p47 overlapped (SI Appendix, Fig. S1K), and suggested
that the UBA domain of p47 does not contribute to the phase 1
inhibitory effect mediated by p47.
Because detailed structures are unavailable for either full-length
p37 or p47, we continued our search for the phase 1 inhibitory
region of p47 by aligning the amino acid sequences of p37 and
p47. We found that amino acids 69–92 in p47 are completely
absent from p37 (SI Appendix, Fig. S3A). To test the role of this
region, we deleted amino acids 69–92 (Δ69–92 p47) and measured
the effects on p97 activity (Fig. 2A, filled red squares). The Δ69–
92 p47 deletion mutant completely abolished phase 1 and showed
enhanced activation in phase 2, compared with WT p47 (Fig. 2A,
filled blue circles). In fact, the WT ATPase activity titration curves
of Δ69–92 p47 resemble the curve for WT p37 (Fig. 2A, filled red
circles), with a single activation phase.
To potentially define the critical residues within amino acids
69–92 of p47, we found six acidic amino acids (one Asp and five
Glu residues) within the region. To evaluate a role for these
acidic residues in phase 1 inhibition, we deleted these acidic
residues (to construct Δ83–90 p47) and also substituted the
acidic amino acids with neutral residues [Asp to Asn and Glu to
Gln, to make a variant designated 83–88 (DE5 to NQ5) p47]. All
proteins [WT p37, WT p47, Δ69–92 p47, Δ83–90 p47, and 83–88
(DE5 to NQ5) p47] formed stable trimers during purification with
a gel-filtration column (Superdex 75 10/300 GL; GE Healthcare).
The purified trimer proteins were reanalyzed to confirm the
formation of stable trimers (SI Appendix, Table S2). As shown
in Fig. 2A, Δ83–90 p47 exhibited a slightly higher inhibitory
phase 1 and a modestly higher phase 2 rebound (filled purple
triangles); on the other hand, the curve of 83–88 (DE5 to NQ5)
p47 overlapped with that of WT p47 (open orange diamonds).
These results ruled out the possibility that electrostatic inter-
actions generated by the negatively charged residues are a direct
cause of the p97 ATPase inhibition, judging by the function of
the three p47 variants. Instead, other interactions and/or the con-
formational differences related to the 69–92 region are needed
for p47 to inhibit p97.
To reaffirm that WT p97 D2-ATPase activity is responsible for
the phase 2 rebound effect with WT p47 (Fig. 1B), we demon-
strated that Δ69–92 p47 activated D2-ATPase activity in p97 with
a Walker B mutation in D1 (D1-E305Q; Fig. 2B, filled purple
squares). In contrast, Δ69–92 p47 did not activate D1-ATPase ac-
tivity in p97 with a Walker B mutation in D2 (D2-E578Q; Fig. 2B,
filled green triangles). Taken together, we established that N-ter-
minal amino acids 69–92 of p47 are responsible for the phase 1
inhibitory effect of WT p47. Removal of this region diminished the
initial inhibitory effect and caused activation of D2-ATPase activity.














Δ69–92 p47 Can Bind to p97 Disease Mutants but Cannot Activate
Their ATPase Activity. Analysis of WT p97 in the presence of
p47 variants in comparison with WT p37 revealed that p47
amino acids 69–92 play a critical role in inhibiting WT p97
ATPase activity (Fig. 2 A and B). As described above, WT
p97 exhibits a rebound in ATPase activity when exposed to WT
p47 at high concentrations (phase 2; Fig. 1B). Because p97 dis-
ease mutants have lost the phase 2 rebound normally associated
with WT p47, we evaluated whether phase 2 activation might
occur for disease mutants exposed to the activating variant (Δ69–
92 p47). As shown in Fig. 2C, even Δ69–92 p47 failed to activate
disease mutants, a result similar to p37 (Fig. 1C). Disease
mutants of p97 remained consistently inhibited in the presence
of WT p47, whereas WT p97 was able to recover at high con-
centrations of p47 (Fig. 2C). To determine whether the lack of
activation of p97 disease mutants by p37 or Δ69–92 p47 was due
to an inability to bind to p97, we used MagneHis Ni-Particles
(Promega) to pull down His-tagged WT or p97 disease mutations
in the presence of p37, p47, or p47 variants. Consistent with
previous findings (42), we observed a strong reduction in the
amount of F253S pulled down, and used this mutant as a control
for no binding (SI Appendix, Fig. S3 A and B, lanes 3 and 8). We
found that the binding of p47, Δ69–92 p47, and p37 to WT p97
(SI Appendix, Fig. S3 B and C, lanes 1–5) was almost identical
to the binding of the disease mutants (lanes 6–10), indicating
that lack of activation in the disease mutants was not due to
differential binding.
We then used surface plasmon resonance (SPR) to quantita-
tively determine binding affinities. WT p47 and deletion p47
mutations bound similarly to WT p97 and disease mutants with
two KD values (∼20 nM and ∼1 μM) (SI Appendix, Fig. S4 and
Table S3). Previous studies using isothermal titration calorimetry
(ITC) determined KD values of 500 nM (43) and 700 nM (44) for
p47–p97 binding, whereas an SPR analysis with immobilized p47
detected a KD of 31.3 nM (45). Our tight KD is very close to the
reported SPR value of 31.3 nM (45), and our weaker KD is closer
to the ITC data. The two different KD values we obtained could
be attributed to one or more of the following: (i) p47 has two
distinct binding sites for p97 (26, 37); (ii) the binding of p47
monomers vs. p47 trimers (37); or (iii) p97 adopts different
conformations that bind cofactors differently. In contrast, the
binding of p37 was best fit to a 1:1 binding model with a KD of
∼20 nM (similar to the tight binding KD for p47). However,
a limitation of this experiment was that at higher p37 concen-
trations (>256 nM), we started to observe significant nonspecific
binding (SI Appendix, Fig. S4A), which prevented the measure-
ment of a potential second binding affinity. Together, our results
indicated that Δ69–92 p47 and WT p47 can bind to WT p97 and
disease mutants similarly. Interestingly, although residues 69–92
in p47 were not important for the direct binding to p97, they do
influence the communication from the N-domain binding sites to
the D1 or D2 domains to activate D2 ATPase activity.
Steady-State Kinetic Analysis of p97–p47 Complexes. We measured
steady-state kinetic constants (kcat, Km, and kcat/Km) to un-
derstand the effects of p47 on regulating WT p97 and its disease
mutants. In comparison with WT p97, the disease mutants
R155H, L198W, and A232E had 2.8- to 3.3-fold higher values of
kcat (the maximum rate of ATP turnover) and 2.9- to 3.6-fold
lower values of Km (the Michaelis Menten constant, the ATP
concentration necessary for half-maximal ATPase activity) (Fig.
3A). Thus, the resulting 9- to 12-fold increase in the apparent
second-order rate constant (kcat/Km), also known as the catalytic
efficiency, indicates an order-of-magnitude increase in the
ATPase rate associated with disease-causing point mutations.
We then evaluated p47 concentration effects on WT and three
disease mutants of p97 under steady-state kinetic conditions and
generated Michaelis Menten curves (Fig. 3 B and C). For WT p97,
12.5 nM p47 lowered both the kcat and Km, by 2.6- and 3.6-fold,
respectively. At 800 nM, p47 lowered the Km by 3.8-fold but had no
effect on the kcat (Fig. 3B). For the A232E p97 mutant, theMichaelis
Menten curve at 12.5 nM p47 was identical to the curve at 800 nM
p47 (Fig. 3C). This striking difference prompted us to evaluate p47
concentration effects more closely for WT p97 and disease mutants
with single mutations in the N domain (R155H), N–D1 linker region
(L198W), and D1 domain (A232E) (Fig. 3 D–F). At low p47 con-
centrations, the kcat and Km ofWT p97 decreased, and as a result the
kcat/Km values were constant up to 12.5 nM p47 (one p47 trimer to
one p97 hexamer). When p47 concentrations were increased further,
the kcat rebounded back to the basal p97 value and the Km remained
low, resulting in a maximum catalytic efficiency (kcat/Km, 4.4-fold
higher, indicated by an arrow in Fig. 3F). The concentration-
dependent effects of p47 on all three disease mutants were similar
for both kcat (Fig. 3D) and Km (Fig. 3E). The kcat values reached
a minimum at 12.5 nM p47, with activities 3.6- to 3.8-fold lower than
the basal level (0 nM p47; red box). The kcat values remained con-
stant through 800 nM p47. The Km values also decreased up to 2.8-
fold, resulting in kcat/Km values less than 2-fold lower than basal
levels (with no p47) (Fig. 3F). Taken together, p47 regulated the
steady-state kinetic behavior of WT and disease mutants in a distinct
manner. ATP binding affinities were increased for WT p97 more
than for the disease mutants, with increasing amounts of p47. On the
other hand, the ATP hydrolysis rates for the disease mutants were
significantly reduced by p47 more so than for WT p97. The overall
Fig. 2. Identification of amino acids 69–92 in p47 as an inhibitory region.
(A) ATPase activities of WT p97 in the presence of p37, p47, and p47 variants
(0–800 nM). n = 6, excluding p47 and Δ69–92 p47 (n = 12). (B) ATPase ac-
tivities of WT and Walker B mutants (D1-E305Q and D2-E578Q) in the
presence of Δ69–92 p47 (0–800 nM). n = 12, excluding E578Q (n = 6).
(C) ATPase activities of WT and disease mutants of p97 in the presence of
p47 versus Δ69–92 p47 (0–800 nM). n = 12, excluding R155H p97 + Δ69–92
p47 (n = 6). All error bars indicate ± SD.
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p47 effect on the catalytic efficiency (kcat/Km) was positive for WT
but negative for disease mutants at higher amounts of p47.
Steady-State Kinetic Analysis of Walker B Mutant p97–p47 Complexes.
To gain a better understanding of how D1 and D2 ATPase ac-
tivities of WT and disease mutants are regulated by p47, we per-
formed steady-state kinetic experiments with Walker B mutants
(which can bind to ATP but cannot hydrolyze it) at D1 (D1-
E305Q) or at D2 (D2-E578Q) for both WT p97 and disease
mutants. We found that at low p47 concentrations, p47 cannot
lower the kcat of the D2 ATPase, when D1 cannot hydrolyze ATP
(see E305Q, Fig. 4A, data in green circles compared with data in
blue circles for WT p97). At 800 nM p47, the kcat of D1-E305Q
becomes substantially greater than that of WT p97. The resulting
kcat/Km curves are similar for WT and D1-E305Q. All of the curves
for D2-E578Q are flat, indicating that p47 does not affect the
kinetic behavior of D1 significantly, when D2 cannot hydrolyze
ATP (Fig. 4 A–C, red circles). The different effects of p47 on WT,
D1-E305Q, and D2-E578Q again confirmed that cofactor-medi-
ated communication between the N domain, D1, and D2 is a dy-
namic process that controls the ATP hydrolysis cycle.
Binding of p47 slightly inhibited D1 catalytic efficiency but
stimulated D2 catalytic efficiency. Cross-inhibition of the maxi-
mal activity of D2 by D1 is much more striking in the presence of
p47. Even at 0.8 nM p47, the kcat of D2 alone (D1-E305Q) is 2.4-
fold higher than that of WT p97 (in which both D1 and D2 can
hydrolyze ATP). At 800 nM p47, the kcat of D2 is 4-fold greater
than that of WT (Fig. 4A). These observations are consistent
with negative cooperativity between the D1 and D2 rings, which
was shown for mouse p97 (46). In addition, recent studies show
that D1 ATP hydrolysis inhibits D2 ATPase activity, and vice
versa (22, 23). We then made double mutants (A232E, D1-
E305Q and A232E, D2-E578Q) to assess the impairment of the
p47-mediated ATPase cycle in a disease mutant of p97. Steady-
state kinetic analysis revealed that D1-E305Q had no effect on
basal kcat and Km values for A232E (Fig. 4 D and E, red boxes).
Thus, the elevated ATPase activity in disease mutants comes
from the kcat of D2 (2.7-fold higher for A232E, D1-E305Q
compared with D1-E305Q). A232E, D2-E578Q was kinetically
identical to D2-E578Q (Fig. 4 A and D), as found in previous
reports (20, 22, 23). Interestingly, p47 had no effect on the kcat of
D2 in the A232E mutant, when D1 lost the ability to hydrolyze
ATP (Fig. 4D, A232E, D1-E305Q, orange circles). This finding
contrasts with the drastic decrease in the kcat of A232E p97 (Fig.
4D, purple circles) with increasing amounts of p47. Another
major difference between WT and A232E is that p47 produced
a greater increase in the Km of A232E, D1-E305Q compared
with D1-E305Q, meaning that p47 decreased the overall catalytic
efficiency (kcat/Km) of A232E, D1-E305Q up to 5-fold (Fig. 4F).
Thus, the p47-regulated ATPase cycle is clearly affected by dis-
ease mutations (Fig. 4). Moreover, the ATP hydrolysis states of
D1 significantly impact how D2 responds to p47. For example,
with WT p97, ATP hydrolysis by D1 blocked activation of D2 by
p47 (as shown by kcat values; Fig. 4A). However, with the disease
mutant, ATP hydrolysis by D1 was required for the enhanced
ATP binding to D2 mediated by p47 (as shown by Km values)
(Fig. 4E). These results strengthen the significance of the dy-
namic communication among the N, D1, and D2 domains during
the ATPase cycle. The apparent steady-state kinetic behavior of
D1 is unaffected by p47. Specifically, neither the overall kcat nor
Km from the six ATP binding sites of D1 appeared to respond to
p47. The presence of D1 ATP hydrolysis had dramatic effects on
how D2 responded to p47, by reducing the ATP hydrolysis rate
(kcat) and by maintaining tighter ATP binding (Km).
Steady-State Kinetic Analysis of p97–p37 Complexes. To evaluate
p37 activation of WT p97 ATPase activity in detail, we performed
steady-state kinetic analysis for WT and A232E in the presence of
800 nM p37 (Fig. 5A). We observed an 11-fold increase in the
catalytic efficiency (kcat/Km) of WT p97, the result of a 2.2-fold kcat
increase and a 5-fold Km decrease. In contrast, the kcat/Km value of
A232E increased only 1.8-fold (Fig. 5A). Given the substantial
difference in p37-regulated ATPase activity between WT and
A232E, we then investigated concentration-dependent effects
Fig. 3. Steady-state kinetic analyses of p47–p97 complexes. (A) Michaelis Menten curves for ATP hydrolysis by WT, R155H, L198W, and A232E mutants of p97.
(B) Michaelis Menten curves for WT, WT with 12.5 nM p47, and WT with 800 nM p47. (C) Michaelis Menten curves for A232E, A232E with 1.6 nM p47, A232E
with 12.5 nM p47, and A232E with 800 nM p47. (D) p47 concentration effects on the turnover number (kcat, min
−1) of WT, R155H, L198W, and A232E. (E) p47
concentration effects on the Michaelis Menten constant (Km, μM) of WT, R155H, L198W, and A232E. (F) p47 concentration effects on the catalytic efficiency
(kcat/Km, M
−1·s−1 × 10−3) of WT, R155H, L198W, and A232E. Experiments were performed using p97 proteins at 4.17 nM hexamer. The 0 nM p47 titration
points are boxed in red. All error bars indicate ± SEM (n = 5).














of p37 for WT p97, D1-E305Q, A232E, and the double mutant
A232E, D1-E305Q (Fig. 5 B and C). For p37 concentrations <6.25
nM, no significant change was detected in kcat values (Fig. 5B). The
kcat values of D1-E305Q started to increase at 6.25 nM and reached
a maximum at 100 nM p37 (increasing from 6.3 to 23.3 min−1). WT
p97 kcat values increased from 6.7 to 15.1 min
−1. A232E kcat values
increased from 19.2 to 25.6 min−1, and those for A232E, D1-E305Q
increased from 17.2 to 29.7 min−1. The p37-mediated increase in
turnover number (kcat) of D2 ATPase activity is higher when D1
cannot hydrolyze ATP for both WT and A232E. These results
confirm the cross-inhibition between D1 and D2 ATPases, as ob-
served previously for p47-regulated ATPase activity (Fig. 4A) and
basal p97 ATPase activity (22, 23).
Regarding the effects of p37 on Km values, p37 decreased the
Km of WT p97 from 180 to 32 μM, but no significant change was
observed for mutant p97 proteins (Fig. 5C). Last, p37 enhanced
the catalytic efficiency (kcat/Km) of WT p97 from 0.6 × 10
3 M−1·s−1
to 6.5 × 103 M−1·s−1 (11-fold), and increased the catalytic ef-
ficiency of D1-E305Q from 1.0 × 103 M−1·s−1 to 6.0 × 103 M−1·s−1
(6-fold). Furthermore, the kcat/Km curve of D1-E305Q was shifted
to the left (Fig. 5D, red arrow). The shift indicates that p37 is a
4-fold more potent activator for D1-E305Q than for WT p97 (Fig.
5D). Consistent with our titration result (Fig. 1C), the maximal
increase in the kcat/Km value of A232E p97 is 1.8-fold, and the kcat/Km
value of the double mutant (A232E, D1-E305Q) decreased
slightly, from 6.8 × 103 to 5.1 × 103 M−1·s−1.
Taken together, the steady-state kinetic analyses revealed that
p37 is a strong activator for WT p97 ATPase activity. The p37
cofactor not only enhanced the rate of ATP hydrolysis (kcat) but
also improved the apparent ATP binding affinity to WT p97
(Km). Interestingly, when D1 was locked in the ADP/ATP-bound
state by a Walker B mutation, p37 was an even more potent
activator for the D2 ATPase, mainly through enhancing the ATP
hydrolysis rate. The activator effect was absent for the p97
disease mutant.
p97-Mediated Postmitotic Golgi Reassembly Assays. To demonstrate
functional importance beyond ATPase activities, we showed that
a disease mutant is hyperactive and less responsive to activation
by p37 in postmitotic Golgi membrane fusion in a well-charac-
terized in vitro reconstitution assay (36, 47). Specifically, the
R155H disease mutant is 2.5 times more active than WT in this
p97-mediated postmitotic Golgi reassembly assay (SI Appendix,
Fig. S5A, compare column 2 with 3). For WT p97, addition of the
p37 trimer at a 1:1 ratio increases the reassembly activity by 6.9-
fold (SI Appendix, Fig. S5A, compare column 2 with 4). At a 1:8
ratio of WT p97 to p37, the reassembly activity increases 11-fold
(SI Appendix, Fig. S5A, compare column 2 with 5). However, for
R155H p97, addition of the p37 trimer at ratios of 1:1 and 1:8
increases reassembly only 3.9-fold (SI Appendix, Fig. S5A, com-
pare column 3 with 6 or 7). We then compared the effects of p37,
p47, and Δ69–92 p47 in the Golgi reassembly assay (SI Appendix,
Fig. S5B). For p47, there is no difference in reassembly between
1:1 and 1:8 ratios of p97 hexamer to p47 trimer complexes (SI
Appendix, Fig. S5B, compare column 3 with 4). Both ratios in-
creased the reassembly activity 7.7-fold (SI Appendix, Fig. S5B,
columns 2–4). When Δ69–92 p47 was added at a ratio of 1:1, we
saw the reassembly activity increase by 7.2-fold (SI Appendix, Fig.
S5B, compare column 2 with 5). At a 1:8 ratio of WT p97 to
Δ69–92 p47, the increase was 12.2-fold (SI Appendix, Fig. S5B,
compare column 2 with 6). The activating cofactor, p37, gener-
ated a 12.2-fold increase in the reassembly activity at a 1:1 ratio
(SI Appendix, Fig. S5B, compare column 2 with 7) and a 13.8-fold
increase at a 1:8 ratio (SI Appendix, Fig. S5B, compare column 2
with 8). Taken together, results from this in vitro reconstituted,
functional p97 assay are consistent with results on ATPase activity.
p47 Improves p97/VCP Disease-Associated Autophagy Impairment.
The ATPase activity and in vitro reconstituted Golgi reassem-
bly results demonstrated a concentration-dependent effect of the
p47 cofactor for WT and disease mutants of p97 proteins. We
reasoned that increased expression of p47 may correct the defect
in autophagy seen in p97 disease mutant-expressing cells. It has
been previously established that the yeast homolog of p47, Shp1,
is essential for autophagosome biogenesis (48), although whether
mammalian p47 behaves similarly has not been established. To
Fig. 4. Concentration-dependent effects of p47 on steady-state kinetic behavior. For WT, D1-E305Q, and D2-E578Q p97 proteins, values of (A) kcat, (B) Km,
and (C) kcat/Km are shown. For A232E and double mutants A232E, D1-E305Q and A232E, D2-E578Q, values are shown for (D) kcat, (E) Km, and (F) kcat/Km.
Experiments were performed using p97 proteins at 4.17 nM hexamer. p47 titrations were performed from 0 nM (boxed in red) to 800 nM. All error bars
indicate ± SEM (n = 5).
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assess this possibility, we expressed mammalian Flag-p47 in hu-
man osteosarcoma U2OS cells and performed an “autophagic
flux” assay (2). In agreement with yeast Shp1, mammalian p47
increased the amount of LC3-II produced, consistent with an ac-
tivation of autophagy (when comparing the increase in LC3-II
protein in SI Appendix, Fig. S6A, lanes 3 and 4). We have pre-
viously established that p97 disease mutations impair autophagic
flux, leading to an accumulation of LC3-II and p62 in U20S cells
stably expressing mutant p97 (2). To see whether p47 could
improve autophagy in these cells, we expressed Flag-p47 and
immunoblotted for LC3 and p62. As previously reported (2), the
steady-state levels of LC3-II and p62 are increased in p97 mu-
tant-expressing cells. Coexpression of p47 decreases the levels of
LC3-II and p62, consistent with a correction in the autophagic
block due to p97 mutations. As shown in SI Appendix, Fig. S6B,
L198W and A232E lines have higher levels of p62 and the lipi-
dated LC3-II (SI Appendix, Fig. S6B, compare lane 7 or 10 with
4). Expression of Flag-p47 results in a significant decrease in p62
and LC3-II (SI Appendix, Fig. S6B, compare lane 7 with 8 or 9 or
lane 10 with 11 or 12). Taken together, these data indicated that
overexpression of Flag-p47 can rescue the defect in p97 disease
mutant overexpression in U2OS cells.
Implications for Future Therapeutic Development by Targeting
Disease Mutants of p97. We previously identified three potent,
ATP-competitive p97 inhibitors (DBeQ, ML240, and ML241; SI
Appendix, Fig. S7A) (49, 50). In addition, Nerviano Medical
Sciences and Genentech identified NMS-873 (SI Appendix, Fig.
S7A) as a potent non–ATP-competitive p97 inhibitor (51, 52).
To investigate whether these four p97 compounds inhibit the
ATPase activity of the R155H p97–p47 complex, IC50 values
were determined for p97 (with BSA as control) and for the p97–
p47 complex (with both WT p97 and R155H; SI Appendix, Fig.
S7 B–E). Compared with the WT p97–p47 complex, NMS-873
was three times more effective and ML240 was two times more
effective against the R155H p97–p47 complex. Our data suggest
that it is possible to develop a mutant–cofactor complex selective
inhibitor or activator. Selective inhibition or activation of the mu-
tant subunit may rescue mutant malfunction within cells. However,
future work will be required to screen for more selective com-
pounds for the disease mutant to further test this hypothesis.
Discussion
Regulation of WT p97 ATPase Activity. Regulation of ATPase or
GTPase activity occurs extensively in nature, through various
control mechanisms. For example, Ras superfamily GTPase ac-
tivation occurs via a canonical nucleotide exchange mechanism,
through binding to guanine nucleotide exchange factor proteins.
These proteins facilitate release of GDP, allowing GTP to bind,
thereby activating the enzyme (53). Another well-characterized
model of regulation involves the 90-kDa heat shock protein
(Hsp90), a dimeric molecular chaperone with weak basal
ATPase activity. Binding to its cochaperone, Aha1 (activator of
Hsp90 ATPase), at a ratio of one Aha1 per Hsp90 dimer stim-
ulates the ATPase activity of Hsp90 by threefold (54). Human
Hsp90 ATPase has a Km value of 324 μM for ATP and a kcat/Km
of 46 min−1·M−1 (55), which is about ninefold less than that of
human p97. With such a low basal ATPase rate, Hsp90 not only
needs an activating cochaperone but also requires inhibiting
cochaperones to reduce activity (56). Additional complexities in
the control of the p97 AAA protein come from occurrence of
intradomain communication within the same protomer and
interdomain communication between neighboring protomers.
For example, interprotomer motion transmission between the
D1 and D2 ATPase domains of p97 has been shown to be critical
for the ERAD (endoplasmic reticulum-associated degradation)
function of p97 (57, 58). Biochemical studies indicate that p97
disease mutations cause defects in interdomain communication
between neighboring subunits (23).
Several p97 cofactors (also called adaptors or interacting
proteins) have been identified, although they have not been
characterized as well as the regulators described above. It is
believed that cofactors of p97 mediate ATPase function and
likely determine substrate selection (59). However, investigators
have not emphasized regulation of p97 ATPase activity by these
proteins. In a recent study, we found that the p47 UBX cofactor
and p97 disease mutations dramatically affect the potency of p97
ATPase inhibitors (22). To facilitate development of potent anti-
p97 drugs, we aim to characterize cofactor-mediated regulation
of this essential AAA enzyme in detail.
Our study provides mechanistic insight into cofactor-regulated
p97 ATPase activity. We initially focused on p47, because it was
Fig. 5. Steady-state kinetic analyses of p37–p97 complexes. (A) Steady-state
kinetic analyses of WT and A232E p97 ATP hydrolysis were performed
with and without 800 nM p37. p97 proteins were used at 4.17 nM hexamer.
(B–D) Dependence of kcat (B), km (C), and kcat/Km (D) values on p37 con-
centration is shown for WT p97 and A232E, D1-E305Q, and a A232E, D1-
E305Q double mutant (4.17 nM hexamer). p37 titrations were performed
from 0 nM (boxed in red) to 800 nM. All error bars indicate ± SEM (n = 5).














the only cofactor previously shown to affect p97 ATPase activity
(30). Through extensive analysis, we demonstrated that regulation
of p97 ATPase by p47 occurs biphasically. We do not have
direct evidence on how this process occurs, but we propose
several explanations. At low p47 concentrations (0.4–12.5 nM
p47 monomer), p47 promotes an ADP-locked state and/or pre-
vents ATP from binding to D1. This inhibits both D1 and D2
ATPases, because the binding of ATP to D1 is required for ATP
hydrolysis by D2 to occur (22, 60, 61). Therefore, locking D1 in
an ADP-bound state prevents ATP from binding and conse-
quently inhibits the activity of both D1 and D2. This explanation
is supported by activity of the Walker B mutant D1-E305Q,
which shows lack of inhibition. Specifically, because the D1 do-
main in the D1-E305Q mutant can bind ATP, but cannot hy-
drolyze it, ATP remains bound, and ATP-bound D1 signals for
D2 to increase its activity in the presence of p47 (Figs. 1D and
4A). In further support of this explanation, there is only slight
inhibition of D1 activity when the mutation occurs in D2 (i.e., the
D2-E578Q mutant) (Fig. 1F). At higher p47 concentrations (25–
800 nM p47 monomer), p47 promotes an open state of D1,
which facilitates more ATP binding to D1. Thus, D2 activity is
stimulated, because more D2 sites are able to hydrolyze ATP
(Figs. 1D and 4A).
We consider possible mechanisms for the transition from
phase 1 (occurring at lower p47 concentrations) to phase 2
(occurring at higher p47 concentrations). Deletion analysis has
shown that p47 has two p97 binding sites (26, 37). Binding affinities
between p97 and p47 indicate two KD values (26 and 1,400 nM) (SI
Appendix, Fig. S4 and Table S3). Therefore, several explanations
for the transition may be possible. For example, (i) self-association
of UBA/UBX domains within the same p47 monomer may occur
at lower p47 concentrations, as suggested for UBXD7 (62). Self-
association may prevent p47 from activating D2. We ruled out this
mechanism by making a ΔUBA variant (47–370 p47), which cannot
self-associate. The titration result was identical to the curve for WT
p47 (SI Appendix, Fig. S1K). Alternatively, (ii) there may be dif-
ferences in p97 conformations for binding at one versus two sites,
or (iii) p47 monomers may assemble into trimers (37). Such trimers
may, in turn, affect how p47 regulates p97 ATPase. Finally, (iv) the
69–92 region of p47, which has a dominant inhibitory effect at
lower p47 concentrations, may induce a conformational change
that allows p97 reactivation in phase 2 in response to higher p47
concentrations. Fig. 6 shows a possible model to explain the tran-
sition caused by p47 monomers and trimers. This model and the
model with two binding sites are not mutually exclusive, because
both models could occur concurrently. For example, the affinities
of two p97 binding sites may differ for p47 monomers and trimers.
The tight binding site may be the main site for p47 monomers,
whereas the weaker binding site may be preferred by p47 trimers—
and this difference may trigger the transition.
Steady-state kinetic analysis revealed that the Km of ATP for
WT p97 falls significantly with increasing amounts of p47 (Fig.
3E), which provides an explanation for why p47 decreases the
potency of p97 ATP-competitive inhibitors but not an allosteric
inhibitor (22). In the presence of p47, ATP binding to WT p97
becomes stronger, and therefore p97 ATP-competitive inhibitors
are unable to inhibit p97 as effectively (compared with p97
alone). We confirmed this result for WT p97–p47 complexes and
also determined the potencies of p97 inhibitors against R155H
p97–p47 complexes (SI Appendix, Fig. S7). NMS-873 (an allo-
steric inhibitor) and ML240 (an ATP-competitive inhibitor) were
two- to threefold more potent against the R155H p97–p47
complex. This result demonstrated that the conformations of the
WT p97–p47 complex and the R155H p97–p47 complex are
likely to be different, thus affecting how inhibitors bind to p97.
Our data suggest that a potential future direction may be to
develop selective inhibitors or activators for mutant–cofactor
complexes and to evaluate their ability to correct the malfunction
of p97 disease mutants.
Our study uncovers p37 as the first p97-activating cofactor, to
our knowledge, which enhances the catalytic efficiency (kcat/Km)
of WT p97 by 11-fold. p37-mediated activation predominantly
affects p97’s D2 activity (SI Appendix, Fig. S1J). Steady-state
kinetic analysis reveals that p37 is an even more potent D2
ATPase activator when D1 cannot hydrolyze ATP (Fig. 5D,
comparing WT with D1-E305Q). Furthermore, p37 reduced the
ATP Km value for WT p97 (Fig. 5C), which suggests that p97
ATP-competitive inhibitors will have difficulty in inhibiting
p97–p37 complexes as well.
Dysregulation of p97 ATPase Activity in Disease Mutants.Differences
between WT and disease mutants of p97 reported previously
suggest that abnormal interactions with p97 cofactors in cells and
the hyperactive D2 ATPase activity for the mutants are the keys
to the pathogenic mechanisms. However, the missing link between
the regulation of ATPase activity and p97 cofactors prompted us
to carry out a simple initial comparison. Specifically, we checked
whether p97 disease mutants could be inhibited by p47. The
results clearly show that the responses to p47 that occur in both
phase 1 and phase 2 are significantly different from what is seen
with WT p97 (Fig. 1B and SI Appendix, Fig. S1B).
p97 activity at 0.4–12.5 nM p47 monomer. The inhibitory effect of p47
on p97 disease mutants at lower p47 levels can possibly occur in
the same way as inhibition of WT p97. At low p47 concentrations
(0.4–12.5 nM p47 monomer), p47 promotes an ADP-locked state
and/or prevents ATP from binding to D1, thereby inhibiting the
ATPase activity of both D1 and D2. This explanation is supported
by the Walker B double mutant, R155H, D1-E305Q, which lacks
strong phase 1 inhibition. The Walker B mutation (E305Q) allows
ATP binding to D1 but prevents ATP hydrolysis (meaning that D1
can bind to ATP but cannot hydrolyze it) (SI Appendix, Fig. S1H,
green squares). Moreover, phase 2 inhibition is also missing for
R155H, D1-E305Q at higher p47 concentrations (25–800 nM p47
monomer). At 0.4–12.5 nM p47 monomer, p47 strongly reduced
the kcat of disease mutants (Fig. 4D), suggesting that p47 can in-
hibit the ATPase rate through an N-domain binding event that
affects D1 and D2 ATPase activities, even at saturating ATP
concentrations.
p97 activity at 25–800 nM p47 monomer. At 800 nM p47, the kcat
values of disease mutants are similar to those of WT p97 (Fig.
4D). However, the kcat values of WT p97 increase from 25 to 800
nM p47, whereas the kcat values of disease mutants remain
constant over 25–800 nM p47, eventually converging with the
WT kcat values at 800 nM p47. In fact, this is the general trend
observed when comparing the Km and the overall kcat/Km values.
Thus, despite the physical and functional differences between
WT p97 and disease mutants, excess amounts of p47 (64 p47
trimers per p97 hexamer) can cause disease mutants to adopt the
same steady-state kinetic behavior as WT p97. We have shown
Fig. 6. Cofactor-induced changes in p97 ATPase activity. Diagram showing
the domain representation of human p97 and the p47 cofactor. Illustrations
depict changes in p97 ATPase activity of WT and disease mutants caused by
the presence of p47.
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that overexpressing p47 can rescue the autophagy defect caused
by overexpression of disease mutants in U2OS cells (SI Appendix,
Fig. S6). More work needs to be done to investigate the potential
of this finding, such as determining whether the disease pheno-
type can be rescued by modifying its behavior.
p97 activity at 0.4–800 nM p37 monomer. To our knowledge, p37 is
the first p97-activating UBX cofactor we identified and has little
effect on disease mutants (Figs. 1C and 5). One possible expla-
nation is that the p97 mutants exist in a hyperactive conforma-
tion that is normally induced by binding to p37. Therefore,
binding of p37 to a disease mutant cannot increase ATPase ac-
tivity above its usual levels. It is also possible that the altered
domains or abnormal interdomain communication caused by the
disease mutation makes p97 unable to communicate the p37
binding effect from the N domain to the D1 and D2 domains of
p97 (SI Appendix, Fig. S8A).
Turning p47 into a p37-Like p97 Activator by Deleting Amino Acids
69–92. Golgi membrane fusion mediated by p97 requires two
distinct cofactors, p47 and p37 (29, 34). The p97–p47 pathway
requires binding to monoubiquitin via the UBA domain of
p47 (amino acids 1–45) (5, 36). The p97–p37 pathway does
not require ubiquitin for its functions (34). p37 lacks the
UBA domain as well as the amino acid region 69–92 found in
p47 (DNRVTSFRDLIHDQDEEEEEEEGQ). The p37 UBX
domain is 63% identical to the p47 UBX domain, and the p37
SEP domain is 72% identical to the p47 SEP domain. By de-
leting amino acids 69–92 from p47, we were able to make a p47
variant (Δ69–92 p47) that behaves like p37 in the p97 ATPase
assay (Fig. 2A) and the Golgi reassembly assay (Fig. 6 and SI
Appendix, Fig. S5). After analysis of two additional p47 var-
iants, Δ83–90 p47 and 83–88 (DE5 to NQ5) p47, we concluded
that the distance generated by 69–92 is the primary determinant
of p37-like behavior, as opposed to the acidic charge of the
linker. More importantly, Δ69–92 p47 failed to activate disease
mutants, which therefore suggests that the same general mech-
anism used by p37 to activate p97 is also used by p47 to cause the
phase 2 rebound of WT p97 (Fig. 6 and SI Appendix, Fig. S8).
Potential Model for the Role of p97 Disease Mutants in Defective
Cofactor-Regulated ATPase Activity. To summarize the results we
have obtained: (i) p97 disease mutants lack a biphasic effect in
the presence of WT p47; (ii) p97 disease mutants cannot be
activated by p37 or by a p47 variant (Δ69–92 p47) that mimics
p37; (iii) p97 disease mutants can be inhibited by WT p47; and
(iv) p97 disease mutants and WT p97 can interact with p37, p47,
or p47 variants in a similar manner, based on pull-down and SPR
experiments. We suggest a possible model by which p97 cofactors
activate the D2-domain ATPase during the ATPase cycle.
Binding at the N domain triggers a conformational change to
convert D1 to the ADP-open state, which allows more ATP to
bind to D1, thereby stimulating the D2 ATPase. This is the
established mechanism by which p97 disease mutants activate D2
activity (20), and explains why no additional activation can be
observed in these mutants (Fig. 6 and SI Appendix, Fig. S8).
In conclusion, our results suggest a general model for cofactor-
regulated p97 ATPase activity involving cofactors that bind to
the N domain of WT p97. In the model, the cofactors induce
conformation changes that regulate ADP/ATP binding to the D1
domain, which in turn controls the D1 and D2 ATPase cycles.
The model is consistent with a recently proposed model ex-
plaining abnormal ATPase activity in p97 disease mutants. An
altered N-domain conformation leads to abnormal ADP/ATP
binding to the D1 domain and causes higher basal D2 ATPase
activity in these disease mutants (23). As further support of our
findings, several other AAA ATPase proteins are also regulated
by cofactors. For example, cytoplasmic dynein is activated by
dynactin–cargo adapter complexes (63). The ER-localized AAA
ATPase Torsin is activated by lamin-associated polypeptide
1 (LAP1). Vps4 ATPase regulates the endosomal sorting complex
required for transport (ESCRT) and is activated by ESCRT-III
and the cofactor Vta1 (64). Finally, the activity of N-ethyl-
maleimide–sensitive factor (NSF) is stimulated by SNAP–SNARE
complexes (65–67).
Although the regulation of p97 activity has been extensively
studied in terms of its intrinsic ATPase activity, more research
remains to be done. Investigation into the differences between
p97’s interaction with p37 and p47, in addition to other
p97 cofactors, will provide a more complete understanding of
cofactor-regulated p97 activity. Furthermore, examination of the
effects of not only cofactors but also substrates on p97 regulation
is a potential future step. We believe that the results of our study
will be critical to unlocking the molecular mechanisms of the
function of WT and disease mutant p97 ATPases and will assist
ongoing efforts to develop therapeutic agents targeting p97
disease mutants.
Materials and Methods
Materials and detailed methods are described in SI Appendix, Methods.
ATPase Assay. Purified p97 (25 μL of 50 μM) was diluted in 30 mL of assay buffer
[10 mL of 5× assay buffer A (1× = 50 mM Tris pH 7.4, 20 mM MgCl2, 1 mM
EDTA), 20 mL water, 50 μL 0.5M TCEP, and 50 μL 10% Triton]. Thirty microliters
of this solution and 10 μL of p97 cofactor (0–4,000 nM) were dispensed into
each well of a 96-well plate, followed by 10 μL of 1,000 μM or 4,000 μM ATP
(pH 7.5). After 35 min at room temperature, the reactions were stopped by
adding 50 μL of BIOMOL Green reagent (Enzo Life Sciences). Absorbance at
635 nm was measured after 4 min. Eight final ATP concentrations were used to
determine steady-state kinetic constants as previously described (22). Michaelis
Menten constants were calculated from 8 replicates using GraphPad Prism 6.0.
Surface Plasmon Resonance. Binding affinities for p37 and p47 cofactors to
p97 proteins were measured on a Biacore 4000 instrument. Neutravidin-coated
sensor chips were prepared as described previously (22), and p97 proteins were
immobilized in 10 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.05%
Tween 20 to 500–600 RU by injecting 4–6 μg/mL protein for 2 min. Binding of
cofactor proteins was measured in 25 mM Tris, pH 7.5, 150 mM NaCl, 10 mM
MgCl2, 0.5 mM TCEP, 0.05% Tween 20, and 0.1% Prionex (Calbiochem) at
20 °C. Sensorgrams were reduced, double referenced, and fit to a 1:1 kinetic
interaction model (p37) or to an equilibrium binding model for a 1:1 in-
teraction (F253S p47) or a 2:1 interaction [WT p47, Δ69-92 p47, Δ83-92 p47,
and 83-88 (DE5to NQ5) p47] in Scrubber 2 (BioLogic Software).
p97-Mediated Postmitotic Golgi Reassembly Assay. The assay was carried out in
vitro as described previously (36, 47). Purified rat liver Golgi stacks were treated
with mitotic cytosol, and the resulting membrane fragments were incubated
with purified p97/p47, p97/Δ69-92 p47, or p97/p37 proteins for reassembly.
Membranes were processed for EM, and the results were quantified to esti-
mate the activity of membrane fusion to form cisternal membranes. Mitotic
Golgi fragments were normalized to 0%. Reassembly with WT p97 (167 nM
hexamer) and p47 (167 nM trimer) was normalized to 100%. The results
represent the mean of at least ten EM images ± SEM.
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